IP Library › Granted Patent US 8,652,508
Granted Patent B2
US 8,652,508 · App. 12/602,054 · Granted Feb 18, 2014

Dietary formulations and methods for treatment of inflammation and other disorders

Inventors: Mark Puder (Medfield, MA); Bruce Bistrian (Ipswich, MA)
Assignees: Children's Medical Center Corporation; Beth Israel Deaconess Medical Center, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,652,508
App. No.
12/602,054
Granted
Feb 18, 2014
Kind
B2
Abstract

Dietary formulations in the form of an oil emulsion providing total enteral or parenteral nutrition, or in the form of food oil suitable for oral administration is provided. The formulations include about 2-60% by calories of a C20 or longer omega-3 fatty acid and about 0.05% to 1% by calories of arachidonic acid, where the formulation provides less than 1% of total calories from linoleic acid and alpha-linolenic acid, and where the fatty acids provide 5-60% of the total calories of said dietary formulation. Methods for treatment of diseases and disorders using the dietary formulations are also provided.

Claims (13)

1. A method of treating essential fatty acid deficiency in a subject,

comprising:

a) administering to said subject a dietary formulation suitable for total enteral nutrition, comprising as the sole source of omega 3 and omega 6 fatty acids:

i. about 2-60% by calories of a C 20 or longer omega 3 fatty acid;

ii. about 0.05% to 1% by calories of arachidonic acid;

iii. from about 0% to <1% linoleic acid; and

iv. from about 0% to <1% alpha-linoleic acid;

wherein the ratio of C 20 or longer omega-3 fatty acid to arachidonic acid is from about 10:1 to about 40:1, and wherein the fatty acids provide 5-60% of the total calories of the formulation;

to thereby alleviate symptoms, diminish disease extent, delay or slow disease progression, or stabilize the condition of the subject.

2. The method of claim 1 wherein the dietary formulation comprises:

a C 20 or longer omega-3 fatty acid consisting of eicosapentaenoic acid (EPA), or docosahexaenoic acid (DHA), or eicosatetraenoic acid, or 5-docosapentaenoic acid, or combinations thereof;

about 0% by calories of linoleic acid; and

about 0% by calories of alpha-linolenic acid.

Continuity (2)
Provisional Application 60931888 · May 25, 2007
Related Publication 20100256235A1 · Oct 7, 2010